top of page
KV Kinisis Ventures Fund RAIF V.C.I.C. Plc

Leading the Future of Diagnostics and Sustainability
What Sets EMBIO Apart?
Pioneering Innovation: Recently awarded two new PCT applications—one for carbon capture technology and another for porous materials activation—EMBIO is pushing the boundaries of diagnostics and sustainability. Flagship Products: Our airbeld™ and B.EL.D platforms deliver unmatched precision, actionable analytics, and seamless integration with corporate ESG initiatives. Global Leadership: A robust intellectual property portfolio, including these groundbreaking PCTs, ensures EMBIO’s leadership in both diagnostics and environmental sustainability

THE COMPANY
EMBIO Diagnostics is at the forefront of technological innovation, revolutionizing the diagnostics industry with cutting-edge sensor solutions. Our mission is to provide real-time, actionable insights that safeguard public health and drive sustainability. Through relentless innovation, we’re transforming how air, water, and food safety are monitored globally
Key Management Team
CEO: Constantinos Loizou (comprehensive background in diverse areas such as research, teaching, and engineering) COO: Lina Kourtella (a rich background in commercialization and international partnerships)
International team of 30
Breaking New Ground in the US Market Why the US?
With its advanced regulatory environment, corporate ESG mandates, and rising focus on sustainability, the US market oers unmatched growth potential. EMBIO is poised to seize this opportunity, providing industry-leading diagnostic solutions that meet evolving demands and set new standards
Key Achievements and Momentum
Revenue Growth: Closed 2024 at €852,000, reflecting 65% YoY growth, with projected revenue to exceed €1.5 million in 2025. Expanding Global Presence: Active in 10+ countries, with a focus on entering the US market by Q3 2025. Strategic Partnerships: Generated over 50 high-value leads at GITEX Global 2024, with strong interest in the US and UAE markets.
STRATEGIC GROWTH IN THE US
Market Entry Strategy
Engaging with urban sustainability projects and corporate leaders to deploy airbeld™ for air quality monitoring and compliance. Launching pilot programs with major US cities to showcase scalable solutions.
Consumer Market Expansion
Launching airbeld™ personal devices on Amazon US in Q4 2025, target ing health-conscious consumers and small businesses. Entering WELL catalogues to engage into international projects, both indoor and outdoor airbeld.
ENTERPRISE SOLUTIONS

Aligning with Fortune 500 companies to integrate EMBIO diagnostics into ESG compliance frameworks. Providing tailored analytics platforms to enhance decision-making and environmental accountability.
Our Value Proposition
EMBIO Diagnostics is more than a diagnostics company—it is a partner in innovation and sustainability. By combining cutting-edge technology, bold vision, and a commitment to global impact, we empower industries to address critical challenges at the intersection of health, environment, and sustainability.
The Opportunity
Join us in revolutionizing the $10 billion diagnostics market. With our advanced technologies, proven track record, and ambitious vision, EMBIO is uniquely positioned to lead this transformation.
Sustainability Commitment
EMBIO targets a 10% reduction in manufacturing waste by 2025 and prioritizes recyclable materials in production, demonstrating our commitment to eco-conscious growth
INNOVATION AT THE CORE
Recent Breakthroughs
2 awarded PCTs: WO2025/003733A1 & WO2024184092 Covering:
Carbon Capture Technology
Pioneering a diagnostic method for monitoring and optimizing carbon capture processes, this innovation supports industries in achieving net-zero goals.
Porous Materials Activation
Leveraging advanced material science, this technology enhances the performance of sensors for more precise environmental monitoring and diagnostics.
EOS Insights Launch: A game-changing feature of airbeld™ that delivers predictive analytics, empowering users with actionable insights for enhanced health and operational e ciency. Blockchain Integration: Advancing data security and transparency through IOTA, ensuring compliance with regulatory standards critical for the US market

For inquiries and partnership opportunities, please contact our CEO, Constantinos Loizou, at k.loizou@embiodiagnostics.eu
bottom of page